CCMINC
FENC icon

Cardinal Capital Management Inc (North Carolina)’s Fennec Pharmaceuticals FENC Stock Holding History

Cardinal Capital Management Inc (North Carolina)’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-26,047
Closed -$272K – 127
2018
Q2 		$272K Buy
26,047
+14,010
+116% +$166K 0.08% 123
2018
Q1 		$145K Hold
12,037
– – 0.05% 121
2017
Q4 		$120K Buy
+12,037
New +$120K 0.04% 120

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cardinal Capital Management Inc (North Carolina)'s FENC Position: Q3 2018 in Review

Cardinal Capital Management Inc (North Carolina) sold out of Fennec Pharmaceuticals (FENC) in Q3 2018, closing a stake of 26,047 shares — an estimated $272K sold.

Cardinal Capital Management Inc (North Carolina) first reported a position in FENC in Q4 2017 and held it in 3 quarters. The position peaked at $272K in Q2 2018. 48 funds tracked by Wall St. Rank hold FENC as of Q3 2018.

  • Cardinal Capital Management Inc (North Carolina) reported no remaining Fennec Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cardinal Capital Management Inc (North Carolina) sold 26,047 Fennec Pharmaceuticals shares in Q3 2018, an estimated $272K.
  • Cardinal Capital Management Inc (North Carolina) first reported a position in Fennec Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Cardinal Capital Management Inc (North Carolina)'s Fennec Pharmaceuticals position peaked at $272K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2018.

Based on Cardinal Capital Management Inc (North Carolina)'s 13F filing for Q3 2018, filed 25 Oct 2018.